Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

ALCAM: A Novel Surface Marker on EpCAMlow Circulating Tumor Cells

Version 1 : Received: 25 June 2022 / Approved: 12 July 2022 / Online: 12 July 2022 (09:11:05 CEST)

How to cite: Charles Jacob, H.K.; Signorelli, R.; Giret, T.M.; Umland, O.; Hadisurya, M.; Lavania, S.; John Lalith, C.R.; Middleton, A.N.; Boone, B.M.; Ergonul, A.B.; Tao, W.A.; Amirian, H.; Iliuk, A.; Khan, A.M.; Diaz, R.A.; Cortes, D.B.; Garcia-Buitrago, M.T. ALCAM: A Novel Surface Marker on EpCAMlow Circulating Tumor Cells. Preprints 2022, 2022070178 (doi: 10.20944/preprints202207.0178.v1). Charles Jacob, H.K.; Signorelli, R.; Giret, T.M.; Umland, O.; Hadisurya, M.; Lavania, S.; John Lalith, C.R.; Middleton, A.N.; Boone, B.M.; Ergonul, A.B.; Tao, W.A.; Amirian, H.; Iliuk, A.; Khan, A.M.; Diaz, R.A.; Cortes, D.B.; Garcia-Buitrago, M.T. ALCAM: A Novel Surface Marker on EpCAMlow Circulating Tumor Cells. Preprints 2022, 2022070178 (doi: 10.20944/preprints202207.0178.v1).

Abstract

Background: Current strategies in circulating tumor cell (CTC) isolation in pancreatic cancer heavily rely on the EpCAM and cytokeratin cell status. EpCAM is generally not considered as a good marker given its transitory change during Epithelial to Mesenchymal Transition (EMT) or reverse EMT. There is a need to identify other surface markers to capture the complete repertoire of PDAC CTCs. The primary objective of the study is to characterize alternate surface bi-omarkers to EpCAM on CTCs that express low or negligible levels of surface EpCAM in pancre-atic cancer patients. Methods: Flow cytometry and surface mass spectrometry were used to iden-tify proteins expressed on the surface of PDAC CTCs in culture. CTCs were grown under condi-tions of attachment and in co-culture with naïve neutrophils. Putative biomarkers were then validated in GEMMs and patient samples. Results: Surface proteomic profiling of CTCs identi-fied several novel protein biomarkers. ALCAM was identified as a novel robust marker in GEMM models and in patient samples. Conclusions: We identified several novel surface bi-omarkers on CTCs expressed under differing conditions of culture. ALCAM was validated and identified as a novel alternate surface marker on EpCAMlow CTCs.

Keywords

Biomarkers; Pancreatic Cancer; CTC; Surfaceome; Protemics; Flow Cytometry; ALCAM

Subject

BIOLOGY, Other

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.

We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.